Financial News
Articles published by Axsome Therapeutics, Inc.
Via GlobeNewswire
Tickers
AXSM
Axsome Therapeutics Announces FDA Acceptance of NDA Resubmission for AXS-07 for the Acute Treatment of Migraine
September 04, 2024
Via GlobeNewswire
Tickers
AXSM
Via GlobeNewswire
Tickers
AXSM
Axsome Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
August 05, 2024
Via GlobeNewswire
Tickers
AXSM
Via GlobeNewswire
Tickers
AXSM
Axsome Therapeutics Settles Sunosi® (solriamfetol) Patent Litigation with Unichem Laboratories
June 05, 2024
Via GlobeNewswire
Tickers
AXSM
Via GlobeNewswire
Tickers
AXSM
Via GlobeNewswire
Tickers
AXSM
Via GlobeNewswire
Tickers
AXSM
Via GlobeNewswire
Tickers
AXSM
Via GlobeNewswire
Tickers
AXSM
Via GlobeNewswire
Tickers
AXSM
Via GlobeNewswire
Tickers
AXSM
Axsome Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
February 20, 2024
Via GlobeNewswire
Tickers
AXSM
Axsome Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on February 20
January 23, 2024
Via GlobeNewswire
Tickers
AXSM
Axsome Therapeutics Hosts Solriamfetol Virtual Investor Event with Expert Thought Leaders Today
December 07, 2023
Via GlobeNewswire
Tickers
AXSM
Via GlobeNewswire
Tickers
AXSM
Axsome Therapeutics to Present at the Piper Sandler 35th Annual Healthcare Conference
November 21, 2023
Via GlobeNewswire
Tickers
AXSM
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.